Climb Bio

2026 Annual Meeting

Meeting Materials

Annual Report

View an enhanced version of our Annual Report.

Proxy Statement

View an enhanced version of our Notice of Meeting & Proxy Statement.

Request Paper Materials

Request paper copies of the proxy materials online now, by email or by phone by dialing 866-648-8133.

Vote Image

Voting

Your vote is IMPORTANT!

Please vote your proxy online now or by phone by dialing 866-506-2806.

Annual Meeting

Date

June 5, 2026

Time

9:00 AM ET

Virtual Meeting

You must register to attend the meeting.

Registration Deadline: June 4, 2026 11:59 PM Eastern Time

About Us

Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy.